Nathaniel Treister1, Stephen Sonis. 1. Brigham and Women's Hospital, Dana Farber Cancer Institute and the Harvard School of Dental Medicine, Boston, Massachusetts 02115, USA.
Abstract
PURPOSE OF REVIEW: Oral mucositis is a common regimen-limiting toxicity of radiation therapy and concomitant radiosensitizing chemotherapy for treatment of head and neck cancers. In addition to its symptomatic impact, oral mucositis increases the likelihood of unplanned breaks or delays in treatment, reduction in chemotherapy dose, use of feeding tube placement or total parenteral nutrition, the need for an intravenous line, opioid use and hospitalization. RECENT FINDINGS: Recent research has demonstrated that chemoradiation-induced mucosal injury is the result of a complex series of biological and cellular events that take place predominantly in the submucosa, with the epithelium being the target tissue. From these findings, novel biologically based preventive treatments are being developed, with a number of agents currently in clinical trials. The implications of recent advancements in radiation therapy treatment planning and delivery are also considered. SUMMARY: Mucositis is a common and serious complication secondary to chemoradiotherapy for head and neck cancer that has a profound effect on morbidity, compliance and treatment outcomes. Currently available interventions are directed at minimizing local radiation exposure and providing symptomatic relief. In the near future, a number of new treatment modalities can be expected to be introduced for reduction of severity and duration of mucositis.
PURPOSE OF REVIEW: Oral mucositis is a common regimen-limiting toxicity of radiation therapy and concomitant radiosensitizing chemotherapy for treatment of head and neck cancers. In addition to its symptomatic impact, oral mucositis increases the likelihood of unplanned breaks or delays in treatment, reduction in chemotherapy dose, use of feeding tube placement or total parenteral nutrition, the need for an intravenous line, opioid use and hospitalization. RECENT FINDINGS: Recent research has demonstrated that chemoradiation-induced mucosal injury is the result of a complex series of biological and cellular events that take place predominantly in the submucosa, with the epithelium being the target tissue. From these findings, novel biologically based preventive treatments are being developed, with a number of agents currently in clinical trials. The implications of recent advancements in radiation therapy treatment planning and delivery are also considered. SUMMARY:Mucositis is a common and serious complication secondary to chemoradiotherapy for head and neck cancer that has a profound effect on morbidity, compliance and treatment outcomes. Currently available interventions are directed at minimizing local radiation exposure and providing symptomatic relief. In the near future, a number of new treatment modalities can be expected to be introduced for reduction of severity and duration of mucositis.
Authors: S F Sencer; T Zhou; L S Freedman; J A Ives; Z Chen; D Wall; M L Nieder; S A Grupp; L C Yu; I Sahdev; W B Jonas; J D Wallace; M Oberbaum Journal: Bone Marrow Transplant Date: 2012-04-16 Impact factor: 5.483
Authors: C L Lazarus; H Husaini; K Hu; B Culliney; Z Li; M Urken; A Jacobson; M Persky; T Tran; C Concert; D Palacios; R Metcalfe-Klaw; M Kumar; B Bennett; L Harrison Journal: Dysphagia Date: 2014-03-08 Impact factor: 3.438
Authors: Mariana de Pauli Paglioni; Karina Morais Faria; Natália Rangel Palmier; Ana Carolina Prado-Ribeiro; Reinaldo Brito E Dias; Henrique da Graça Pinto; Nathaniel Simon Treister; Joel B Epstein; César Augusto Migliorati; Alan Roger Santos-Silva; Thais Bianca Brandão Journal: Lasers Med Sci Date: 2020-07-05 Impact factor: 3.161